Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101254 · ClinicalTrials.gov registry record · Phase 1
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03101254 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT03101254, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib
Interventions
- DRUG Vemurafenib
- DRUG Cobimetinib
- DRUG LY3022855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2020-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03101254
The ClinicalTrials.gov registry entry for NCT03101254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vemurafenib is the first listed.
NCT03101254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03101254 about?
NCT03101254 is a clinical study titled "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma". This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib
What is the current status of trial NCT03101254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-06-06. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT03101254?
The interventions under investigation include: Vemurafenib (DRUG), Cobimetinib (DRUG), LY3022855 (DRUG).
Who is sponsoring clinical trial NCT03101254?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.